ADO Charting and Technical Analysis, page-2160

Astra Zeneca seeks emergency approval from the FDA for its new antibody therapy;
together with the developments from Merck, COVID becomes more and more manageable for breakthrough and immo-compromised individuals.

The antibody therapy, called AZD7442, was 77% effective in reducing the risk of developing Covid-19 symptoms among people who received the drug as a preventive measure, AstraZeneca said in a press release, citing its Phase III trail featuring over 5,000 participants.
According to the drugmaker, the antibody cocktail could be used to protect people who may not develop a robust immune response to Covid-19 vaccines.